UroGen Pharma Ltd. - Ordinary Shares (URGN) Social Stream



UroGen Pharma Ltd. - Ordinary Shares (URGN): $9.27

-1.75 (-15.88%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add URGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 401

in industry

UROGEN PHARMA LTD (URGN) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering UROGEN PHARMA LTD.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-08-05 5 $55 $30 $46.5 $10.39 347.55%
2021-11-11 4 $55 $30 $46.5 $10.39 347.55%
2021-11-16 4 $51 $30 $44 $10.39 323.48%
2022-03-02 5 $51 $30 $40 $10.39 284.99%
2022-03-23 4 $51 $17 $31 $10.39 198.36%
2022-04-27 6 $51 $17 $27 $10.39 159.87%
2022-07-21 5 $51 $17 $27 $10.39 159.87%
2022-08-12 6 $51 $17 $27 $10.39 159.87%
2022-08-15 6 $51 $17 $29.8 $10.39 186.81%
2022-10-26 6 $51 $20 $34.4 $10.39 231.09%
2022-11-10 6 $51 $20 $33.4 $10.39 221.46%
2022-11-14 6 $47 $20 $32.6 $10.39 213.76%
2022-11-23 6 $47 $20 $30.8 $10.39 196.44%
2022-12-20 6 $47 $20 $30.2 $10.39 190.66%

The Trend in the Analyst Price Target


URGN's average price target has moved down $8.97 over the prior 18 months.

URGN reports an average of 288.48% for its upside potential over the past 42 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2022-03-02 5 51 30 40.0 6.07 558.98%
2022-05-11 6 51 17 27.0 6.03 347.76%
2022-08-12 6 51 17 27.0 8.53 216.53%
2022-10-18 6 51 20 34.4 11.87 189.81%
2022-11-14 6 47 20 32.6 9.16 255.9%

URGN Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 6 0 0 0 0 6

The Trend in the Broker Recommendations


Over the past 153 days, URGN's average broker recommendation rating improved by 0.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for URGN as an investment opportunity.

  • In the context of all US stocks, UROGEN PHARMA LTD's upside potential (average analyst target price relative to current price) is higher than 1400.65% of them.
  • In terms of how UROGEN PHARMA LTD fares relative to all US stocks, note that its variance in analysts' estimates is lower than -1136.3% of that group.
  • To contextualize these metrics, consider that out of all US stocks, UROGEN PHARMA LTD's number of analysts covering the stock is higher than 407.52% of them.
  • In the context of stocks in the small market cap category, UROGEN PHARMA LTD's average analyst price target is higher than 1245.28% of them.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to UROGEN PHARMA LTD are PRTK, VBIV, and ATNF.

Is URGN a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7642 seconds.